Biotest AG: Biotest Group reports increase of EBIT
Biotest AG / Key word(s): Quarter Results Biotest Group reports increase of EBIT - EBIT up 13.5% at EUR 11.8 million - Sales increased to EUR 118.7 million - Management Board confirms guidance Dreieich, 8 May 2013. In the first three months of financial year 2013 the Biotest Group was able to significantly increase sales again and achieve a new quarterly sales record. In the reporting period the Group generated revenues of EUR 118.7 million compared to EUR 107.7 million in the same quarter of the previous year. This represents an increase of Profitability also increased significantly. Earnings before interest and taxes (EBIT) increased in the reporting period by 13.5 % from The growth in sales was driven primarily by the international markets. Whereas there was slight growth in Europe, sales in the US increased significantly. The market launch of Bivigam(R) in February 2013 was the main reason for the double-digit growth in this market. The marketing authorisation of Bivigam(R) by the US Food and Drug Administration (FDA) as well as the market launch of the product represent important milestones for Biotest. The Biotest Group estimates a sales potential of about USD 100 million over the medium to long term for this immunoglobulin used to treat patients with primary humoral immune deficiencies. The business performance of the Biotest Group continues to be very positive. For this reason the Management Board reaffirms its target of increasing sales by 10 % to 15 % in the current year. The management expects a similar increase in EBIT. The three-months report is available on the company's website at http://www.biotest.de/ww/de/pub/investor_relations/publikationen/quartalsberichte.cfm Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 End of Corporate News 08.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | Biotest AG | |
| Landsteinerstraße 5 | ||
| 63303 Dreieich | ||
| Germany | ||
| Phone: | 0 61 03 - 8 01-0 | |
| Fax: | 0 61 03 - 8 01-150 | |
| E-mail: | investor_relations@biotest.de | |
| Internet: | http://www.biotest.de | |
| ISIN: | DE0005227235, DE0005227201 | |
| WKN: | 522723, 522720 | |
| Indices: | SDAX | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart | |
| End of News | DGAP News-Service |
| 210028 08.05.2013 |